Recorded Presentation: From mAb to bAb
Developing drugs requires navigating complex technical, practical, and strategic challenges quickly. Optimizing a drug’s activity and effectiveness and subsequently considering the IP landscape are crucially important balancing acts. Here, we demonstrate how evitria’s extensive expertise in antibody production can help you engineer, reformat, and produce your therapeutic, using a case study for the transformation of a mAb into a bsAb.
Desmond Schofield
evitria AG
Chief Business Officer
As Chief Business Officer, Desmond Schofield leads strategic initiatives focused on fostering growth and innovation. His responsibilities include crafting and implementing strategies to enhance customer service and satisfaction within a constantly evolving market.
7 reasons for us to choose Chinese hamster ovary (CHO) cells for recombinant protein production
Bispecific antibody production – a comprehensive overview
Fc Silenced Antibody – Therapeutic antibodies with reduced side effect profile